Opportunities to Address the Hepatitis C Epidemic in the Correctional Setting

Boutwell, Amy E.; Allen, Scott; Rich, Josiah D.

doi:10.1086/427455

Cited by 32 publications

(27 citation statements)

References 21 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4] The prevalence of hepatitis C virus (HCV) infection among inmates in the United States is substantially higher than that of HIV infection, ranging from 12% to 35%, and up to one-third of those with HCV infection have passed through a correctional facility; however, HCV testing is not routinely provided in correctional facilities. 5,6 In the U.S., it is estimated that only 25%-50% of those who have HCV infection have been diagnosed. 6,7 Recent recommendations have emphasized the need to expand and integrate services to provide HCV screening and care through existing HIV services and other public health programs.…”

mentioning

confidence: 99%

Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: An Integration Pilot Initiative in a Massachusetts County Correctional Facility

et al. 2014

View full text Add to dashboard Cite

Objectives. The Massachusetts Department of Public Health (MDPH) and the Barnstable County Sheriff's Department (BCSD) in Massachusetts initiated a pilot program in July 2009 offering education and hepatitis C virus (HCV) antibody testing to inmates and detainees, concurrent with routine HIV testing . The initiative was implemented to assess the feasibility of integrating HCV screening into an HIV screening program in a correctional setting and the efficacy of linking HCV antibody-positive inmates to clinical care upon release .Methods. Through the Screening for Hepatitis C as a Prevention Enhancement initiative, HCV and HIV testing were offered to inmates and detainees shortly after admission, and by request at any time during incarceration. In preparation for release, referrals were made to community-based medical providers for HCV follow-up care . Data from BCSD were compared with routine surveillance data received by MDPH . Confirmatory HCV test results received by April 15, 2012, were considered indicators of appropriate post-release clinical care .Results. From July 2009 through December 2011, 22% (n5596) and 25% (n5667) of 2,716 inmates/detainees accepted HCV and HIV testing, respectively . Of those tested for HCV antibody, 20 .5% (n5122) were positive . Of those tested for HIV antibody, 0 .8% (n55) were positive . Of the inmates who tested HCV positive at BCSD and had been released, 37 .8% were identified as receiving post-release medical care .Conclusions. We determined that integration of HCV education and screening into correctional facilities is feasible and reveals high rates of HCV infection . Although this model presupposes programmatic infrastructure, elements of the service design and integration could inform a range of correctional programs . Effective linkage to care, while substantial, was not routine based on our analysis, and may require additional resources given its cost and complexity.

show abstract

mentioning

confidence: 99%

Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: An Integration Pilot Initiative in a Massachusetts County Correctional Facility

et al. 2014

View full text Add to dashboard Cite

show abstract

“…HCV is possibly the most prevalent bloodborne infection in prisons in the United States. [7][8][9][10][11] An increase in deaths from liver disease among inmates has been observed. 12 The need to identify and treat inmates with HCV has been highlighted by both correctional and public health officials.…”

mentioning

confidence: 99%

Promoting HCV Treatment Completion for Prison Inmates: New York State's Hepatitis C Continuity Program

et al. 2007

View full text Add to dashboard Cite

SYNOPSISThis article describes the development of a statewide program providing continuity of hepatitis C virus (HCV) treatment to prisoners upon release to the community. We discussed length of stay as a barrier to treatment with key collaborators; developed protocols, a referral process, and forms; mobilized staff; recruited heath-care facilities to accept referrals; and provided short-term access to HCV medications for inmates upon release. The Hepatitis C Continuity Program, including 70 prisons and 21 health-care facilities, is a resource for as many as 130 inmates eligible to start treatment annually. Health-care facilities provide fairly convenient access to 87.1% of releasees, and 100% offer integrated HCV-human immunodeficiency virus/acquired immunodeficiency syndrome care. As of March 2006, 24 inmates had been enrolled. The program was replicated in the New York City Rikers Island jail. The program is operational statewide, referrals sometimes require priority attention, and data collection and other details are still being addressed.

show abstract

“…The introduction of biologics was timed to address the growing need for mechanism-based drug therapies for diseases such as hepatitis, HIV and cancer [1]. These medicines are composed of very large and complex molecules (i.e.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis Foundation International Biosimilars Issue Brief

Cameron¹

2016

JLRDT

View full text Add to dashboard Cite

Biosimilars are biological medical products highly similar to the original products manufactured by different pharmaceutical companies. Biosimilars inherit a critical role that addresses the growing need for mechanism-based drugs needed to treat diseases such as hepatitis, HIV and various cancers. In this issue brief, the developmental background, approval process, regulatory review and safety procedures and naming process will be discussed in detail. Benefits and cost to the patient population will also be examined, contrasting how biosimilars can be interchanged or substituted with other drugs to produce near identical health outcomes at affordable prices. Although biosimilar development appears promising, guidelines to proper labeling and surveillance of adverse effects are still being conducted. Patients tend to respond differently to drug therapies, making biosimilars the patient-specific treatment alternative. The Food and Drug Administration (FDA) continues to expand on its recommendations to improve regulation, safety precautions and transparency across all levels of health care for medical providers and their patients.

show abstract

Opportunities to Address the Hepatitis C Epidemic in the Correctional Setting

Cited by 32 publications

References 21 publications

Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: An Integration Pilot Initiative in a Massachusetts County Correctional Facility

Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: An Integration Pilot Initiative in a Massachusetts County Correctional Facility

Promoting HCV Treatment Completion for Prison Inmates: New York State's Hepatitis C Continuity Program

Hepatitis Foundation International Biosimilars Issue Brief

Contact Info

Product

Resources

About